Rationale: Phosphorylation of ␤ 2 -adrenergic receptor (␤ 2 AR) by a family of serine/threonine kinases known as G protein-coupled receptor kinase (GRK) and protein kinase A (PKA) is a critical determinant of cardiac function. Upregulation of G protein-coupled receptor kinase 2 (GRK2) is a well-established causal factor of heart failure, but the underlying mechanism is poorly understood.
D espite major developments in both diagnosis and treatment, heart failure (HF) continues to be a leading cause of death and disability in Western countries and will become the number-1 killer worldwide in 2020. 1 It has been controversial as to whether increased cAMP-protein kinase A (PKA) signaling is beneficial or detrimental in the context of HF. Patients with HF exhibit chronically enhanced PKA signaling, 2, 3 and transgenic mouse models with cardiac specific overexpression of ␤1 adrenergic receptor (AR), 3 the a-subunit of G s , 4 and the catalytic subunit of PKA 5 display HF phenotypes, suggesting that overtly enhanced PKA sig-naling is cardiac detrimental. Over the past 2 decades, compelling evidence indicates that phosphorylation of ␤ARs by another family of serine/threonine kinases known as GPCR kinases (GRKs) in the heart is a critical determinant of cardiac function and has been implicated in many pathological conditions including HF. 6 In humans or animal models with HF, chronic catecholamine elevation causes marked dysregulation of ␤ARs, resulting in various molecular abnormalities, including upregulation of GRK2 and pertussis toxin (PTX)-sensitive G i proteins. Upregulation of both of these proteins have been implicated as causal factors in the devel-opment of HF. In particular, GRK2 is the most abundant and best-characterized GRK in the heart. 7 GRK2 expression and activity are markedly elevated and play a central role in the HF-associated defect in ␤AR signaling and cardiac dysfunction. Myocardial ischemia and hypertension in humans and animal models have also been associated with elevated GRK2 expression and activity. 6 These previous studies have defined GRK2 upregulation as an early common event in cardiac maladaptive remodeling and HF.
It has been shown that phosphorylation of ␤ 2 AR plays a crucial role in regulating differential G protein coupling of the receptor. Specifically, ␤b 2 AR phosphorylation by PKA mediates the switch of coupling from G s to G i. . 8, 9 Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway ␤ 2 AR physiological signaling. 10 Further studies have demonstrated that ␤ 2 AR coupling to G i may be also dependent on the receptor internalization and recycling. [11] [12] [13] However, it is unclear whether GRK-mediated phosphorylation of ␤ 2 AR is involved in the regulation of ␤ 2 AR-coupled G i signaling in heart. Because both GRK2 and G i proteins are significantly elevated in HF caused by a multitude of etiologies, 14 -19 we hypothesize that the welldocumented detrimental effects of GRK2 in the failing heart may causatively link to enhanced ␤ 2 AR-coupled G i signaling.
In the present study, we explored the mechanism that links pathological upregulation of GRK2 to the development of HF. We found both in vivo and in vitro that enhanced ␤ 2 AR phosphorylation by GRK2 leads the receptor to G i -biased signaling and that inhibition of the G i signaling blocks HF in transgenic (TG) mice with cardiac-specific overexpression of GRK2 (GRK2-TG) or of a ␤ 2 AR mutant lacking all of the PKA phosphorylation sites (PKA-TG) subjected to pressure overload, marking G i -biased ␤ 2 AR signaling as a primary event linking upregulation of GRK2 to cardiac maladaptive remodeling and failure.
Methods
An expanded Methods section is provided in the Online Supplement at http://circres.ahajournals.org.
Generation of TG Mice
Flag-tagged human ␤ 2 AR mutants lacking either the putative GRK phosphorylation sites (GRKϪ) or the putative PKA phosphorylation sites (PKAϪ) (Figure 2A and 2B) were subcloned into a pBluescriptbased transgenic vector downstream of ␣-myosin heavy chain gene promoter and upstream of the SV40 polyadenylation site. The detail sequences of the ␤ 2 AR PKAϪ Ϫ and GRKϪ mutants were presented in Figure 2B . Transgenic mice with cardiac-specific overexpression of wild-type human ␤ 2 AR (WT-TG) were imported from Dr Gerald Dorn's Laboratory.
Animal Models
We used male nontransgenic mice (NTG), transgenic mice with cardiacspecific overexpression of wild-type human ␤ 2 AR (WT-TG) or PKAphosphodeficient ␤ 2 AR (PKA-TG), or GRK-phosphodeficient ␤ 2 AR (GRK-TG) and their littermate controls at 12-16 weeks of age. In addition, male transgenic mice with cardiac-specific overexpression of GRK2 (GRK2 TG) and their littermate control mice (LC) were used in a subset of experiments. Pressure overload was produced by transverse aortic constriction (TAC) as previously described. 20
Supplemental Materials on Detailed Methods
See the Online Supplement Materials for detailed methods regarding in vivo assessment of mouse cardiac contractility by echocardiography and Millar system, radioligand binding assay, Western blot analysis, adult mouse cardiac myocyte culture and adenoviral gene transfer, cardiomyocyte contraction measurements, histological analysis, cAMP assay, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and statistical analysis.
Results

Overexpression of GRK2 Causes ␤AR Dysfunction by Enhancing G i Signaling in Cultured Cardiomyocytes and In Vivo
We have recently demonstrated that G i -biased ␤ 2 AR signaling is dependent on agonist stimulation and that prolonged absence of agonist stimulation leads to uncoupling of ␤ 2 AR from the G i signaling, as is the case in adult mouse cardiomyocytes cultured for 24 hours. 21 Consistent with the previous notion, in adult mouse cardiomyocytes cultured and infected by adenovirus-␤-Gal for 24 hours, ␤ 2 AR stimulation with zinterol led to a full contractile response which was insensitive to PTX treatment (Figure 1 A and 1B). Importantly, overexpression of GRK2 with adenoviral gene transfer suppressed ␤ 2 AR-mediated contractile response and the inhibitory effect of GRK2 was fully abolished by disrupting G i signaling with PTX ( Figure 1A and 1B). Prolonged stimulation of cardiomyocytes with isoproterenol (ISO, 1 nmol/L) in the presence or absence of PTX did not change the expression of GRK2 (Online Figure I) . These results demonstrate, for the first time, that overexpression of GRK2 enhances G i -biased ␤ 2 AR signaling. To further determine whether in vivo overexpression of GRK2 in the heart can facilitate ␤ 2 AR-coupled G i signaling and, if so, whether the enhanced G i signaling is involved in GRK2-mediated ␤AR dysfunction, we took advantage of transgenic mice with cardiac-specific overexpression of GRK2. 22 Consistent with our previous studies on these mice, 22 in vivo experiments revealed that ␤AR-induced increases in cardiac contractility and relaxation, as measured by left ventricular (LV) ϩdP/dt max and ϪdP/dt min , respectively, were markedly suppressed in mice overexpressing GRK2 (GRK2 TG mice) compared with wild-type littermate controls ( Figure 1C and 1D). Remarkably, disruption of G i signaling with Figure 1C and 1D), indicating that overexpression of GRK2-induced cardiac ␤AR dysfunction is mediated by enhanced G i signaling.
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Augmentation of GRK-Mediated ␤ 2 AR Phosphorylation Leads to Exacerbated Cardiac Hypertrophy, HF, and Early Mortality in Response to Pressure Overload
Because ␤ 2 AR can be phosphorylated by at least 2 types of protein kinases, PKA and GRK (Figure 2A ), we sought to distinguish the potential role of GRK-versus PKA-mediated ␤ 2 AR phosphorylation in the pathogenesis of HF in vivo. The experiments took advantage of 3 different transgenic mouse models that we developed: mice cardiac-specifically overexpressed the WT human ␤ 2 AR (WT-TG) or ␤ 2 AR mutants in which all of the PKA phosphorylation sites or all of the GRK phosphorylation sites were substituted by alanine (A) or glycine (G) (namely PKA-TG or GRK2-TG, respectively) ( Figure 2 A and 2B) at a matched receptor density ( Figure  2C ). The receptor densities in hearts from WT-TG, PKA-TG, and GRK-TG mice were detected by radioligand binding assay (856Ϯ45, 828Ϯ33, and 850Ϯ23 fmol/mg protein, nϭ3-4, respectively) ( Figure 2C ). As compared with NTG mice, overexpression of the WT ␤ 2 AR led to profoundly increased phosphorylation of ␤ 2 AR at both GRK and PKA sites assayed by site-specific antibodies ( Figure 2D ). As expected, PKA-TG mice showed a clear increase in phosphorylation of ␤ 2 AR by GRK but not PKA, whereas GRK-TG mice exhibited augmented phosphorylation of ␤ 2 AR by PKA but not GRK ( Figure 2D ).
Thus, GRK-and PKA-mediated phosphorylation of ␤ 2 AR was selectively enhanced in PKA-TG and GRK-TG mice, respectively.
To investigate whether ␤ 2 AR phosphorylation by GRK and PKA is differentially involved in the regulation of cardiac structure and function, NTG or PKA-TG, GRK-TG, or WT-TG mice were subjected to pressure overload by TAC. There was no obvious phenotypic difference in cardiac anatomy and function among the genotypes under resting conditions at 4 -5 months old of age, as assessed by echocardiography ( Figure 3A and 3B). However, after TAC for 5 weeks, PKA-TG mice developed severe LV dilation and contractile dysfunction ( Figure 3A and 3B) and increased mortality rate ( Figure 3C ). Cardiac dysfunction occurred as early as 1 week after TAC and was progressively worse as TAC continued only in PKA-TG mice ( Figure 3B ). In contrast, GRK-TG mice were not different from NTG or WT-TG mice in terms of cardiac anatomy and function in response to TAC. Furthermore, PKA-TG mice displayed markedly exaggerated cardiac hypertrophic response to TAC, as manifested by significantly increased heart size ( Figure 4A ), heart/body ratio ( Figure 4B ), and cardiomycoyte size (Online Figure II) . It is also important to note that PKA-TG mice but not NTG or WT-TG or GRK-TG showed increased fibrosis after TAC for 5 weeks ( Figure 4C and 4D). Thus, pressure overload led to more severe ventricular dilation with increased end-diastolic and end-systolic dimensions, reduced fractional shortening ( Figure 3 ) and exacerbated cardiac maladaptive remodeling ( Figure 4 ) in PKA-TG mice but not in other groups including NTG, WT-TG, and GRK-TG mice. 
Accelerated HF of PKA-TG Mice Is Associated With Enhanced ␤ 2 AR-Coupled G i Signaling
More detailed examination of cardiac function was carried out by invasive pressure-volume analysis. Pressure-volume loops were measured before and during transient reduction of chamber preload to generate specific end-systolic (ESPVR) and end-diastolic (EDPVR) pressure-volume relations (Figure 5) . After TAC for 5 weeks, NTG hearts had enhanced effective arterial elastance (Ea; an index of total ventricular afterload) and slope of end-systolic pressure-volume relation with reduced ejection fraction, characteristics of hypertrophy induced by sustained pressure overload. Under resting conditions, PKA-TG, GRK-TG, and WT-TG mice had similar increases in LV peak systolic pressure and basal systolic function with a slight upward and leftward shift of their ESPV compared with NTG mice. TAC for 5 weeks triggered distinct phenotypes between PKA-TG mice and GRK-TG or WT-TG mice in terms of the progression of cardiac dysfunction. As shown by the representative examples, in the GRK-TG and WT-TG mice, enhancements in resting Ea and slopes of ESPVR (before TAC) were slightly increased after 5 weeks of TAC, consistent with a functional response with feature of cardiac hypertrophy ( Figure 5A ). This did not occur in PKA-TG mice. Notably, PKA-TG mice displayed ventricular dilation, suppressed ϩdP/dt, reduced Ea, decreased ejection fraction associated with a rightward shift of pressure-volume relation, and a decrease in the slope of end-systolic pressure-volume relation ( Figure 5A and 5B). After 5 weeks of TAC, PKAϪ mice demonstrated a more significant decrease in maximal rate of pressure decline (ϪdP/dt), although a relaxation index tau was comparable in GRK-TG, and PKA-TG mice ( Figure 5C ).
The aforementioned data clearly indicate that PKA-TG mice are more vulnerable to pressure overload, suggesting that selectively enhancing ␤ 2 AR phosphorylation by GRK but not PKA profoundly exacerbates pressure overloadinduced cardiac maladaptive remodeling and dysfunction. Next, we sought to decipher the mechanism underlying the distinct phenotypes of PKA-TG mice versus those of GRK-TG mice. Western blotting revealed that the increases in GRK2 and G i protein abundance were significantly greater in hearts from PKA-TG mice relative to hearts from NTG or WT-TG or GRK-TG mice, although both GRK2 and G i proteins were markedly elevated in all genotypes after 5 weeks TAC ( Figure 6A and 6B) . Concomitantly, hearts from PKA-TG mice failed to compensate pressure overload even 1 week after TAC, resulting in significantly diminished cardiac contractility in PKA-TG mice compared with that in other genotypes (NTG or WT-TG or GRK2-TG) ( Figure 6C ). Importantly, disruption of the G i signaling with PTX treatment minimized the difference between PKA-TG mice and other groups ( Figure 6C ). In fact, in an early stage of HF (1 week after TAC), PTX treatment fully restored cardiac function in PKA-TG mice, whereas in the later stage of HF (5 Figure 2 . Transgenic mice with cardiac-specific overexpression of wild-type (WT) human ␤ 2 AR or its mutants lacking PKA or GRK phosphorylation sites. A, Schematic presentation showing ␤ 2 AR phosphorylation sites for PKA or GRK. B, The specific sequences of WT ␤ 2 AR or its mutants lacking PKA (PKAϪ) or GRK (GRKϪ) phosphorylation sites. C, The ␤ 2 AR density was 9.6Ϯ1.3 fmol/mg protein and total ␤AR density was 28.6Ϯ3.4 fmol/ mg protein in NTG mice (nϭ6). In transgenic mice, ␤ 2 AR density was 856Ϯ45, 828Ϯ33, and 850Ϯ23 fmol/mg protein for WT-TG, PKA-TG, and GRK-TG mice, respectively, (nϭ6 for each group). D, Phosphorylation of ␤ 2 AR in PKA or GRK sites were assayed by Western blot using a site-specific antibody reacting with phosphorylated ␤ 2 AR at a PKA site (aa262) or GRK sites (aa355 and aa366). The antibodies were raised against the peptides CDRTGHGLRRSpSKF-NH2 for the anti-pSer262 PKA site (clone 2G3) and CKAYGNGYpSpSNGN-NH2 for the anti-pS (Ser355, 356) (clone 5C3). Total expression of ␤ 2 AR in transgenic mouse hearts was detected by Western blot using an antibody reacting with ␤ 2 ARs. weeks after TAC), PTX substantially improved cardiac function in PKA-TG mice ( Figure 6C ), highlighting that enhanced GRK2 and subsequent enhancement of G i -biased ␤ 2 AR signaling play a crucial role in the triggering and worsening TAC-induced cardiac maladaptive remodeling and failure.
In principle, the cardiac dysfunction in PKA-TG mice could be due to an enhancement in the receptor to G i signaling for attenuation of tonic cAMP signaling or due to cardiac adaptive remodeling for structure changes in myocardium or both alterations. To further investigate this issue, we measured basal and ISO-induced cAMP formation in cardiomyocytes from NTG or TG mice expressing WT or mutant ␤ 2 AR. The present data demonstrated that spontaneous ␤ 2 AR activity is increased in all of the transgenic mice expressing WT or mutant ␤ 2 AR, as evidenced by their increased cAMP baselines ( Figure 6D and Online Figure III) , consistent with the hemodynamic data ( Figure 5 ). It is noteworthy that the decay of ISO-induced cAMP accumulation declines faster in cells from PKA-TG mice than that in cells from WT-TG or GRK-TG mice. Because the decay of ISO-induced cAMP accumulation is sensitive to PTX, our data indicates that ␤ 2 AR/G i coupling is enhanced in PKA-TG mice. Thus, the cardiac dysfunction of PKA-TG mice probably is due to enhanced G i signaling, which, in turn, contributes to cardiac adaptive remodeling and the progression of HF.
Discussion
The present study has revealed 3 major findings. First, phosphorylation of ␤ 2 AR by GRK as well as PKA is a primary determinant of the receptor-coupled G i signaling. Second, overexpression of GRK2 enhances G i -biased ␤ 2 AR signaling, which subsequently negates cardiac contractile response to ␤AR stimulation in a PTX-sensitive manner in GRK2 transgenic mice and cultured mouse cardiomyocytes. Third, selective augmentation of GRK-mediated ␤ 2 AR phosphorylation in PKA-TG mice renders the heart more vulnerable to pressure overload and inhibition of G i signaling can restore cardiac function of PKA-TG mice. In contrast, a selective increase in PKA-mediated phosphorylation of ␤ 2 AR does not affect cardiac response to pressure overload in GRK-TG mice compared with NTG or WT-TG mice. Therefore, we conclude that cardiac detrimental effects of GRK2 upregulation are mediated, at least in part, by enhanced ␤ 2 AR-coupled G i signaling, which, in turn, contributes to the pathogenesis and progression of HF. Thus, both GRK2 and ␤ 2 AR-coupled G i signaling may offer novel therapeutic opportunities for the treatment of HF.
Role of GRK2 in Normal and Failing Hearts
In our previous studies, we have shown that cardiac-specific overexpression of GRK2 to the levels seen in human HF suppresses cardiac contractile response to ␤AR stimulation with ISO, 22 indicating that myocardial overexpression of GRK2 triggers ␤AR desensitization in vivo. In contrast, overexpression of the peptide inhibitor of GRK2, GRK2-ct, enhances cardiac contractility and relaxation. 22 Thus, GRK2 expression level has an important impact on cardiac performance under normal conditions. This perception has been further elucidated in recent studies on GRK2 knockout mouse models. 32 In the failing heart, adrenergic overdriving occurs early in the progression to HF, as evidenced by increased catecholamine levels before the onset of HF. 33 As a result, the expression and activity of GRK2 are elevated in the failing heart. Previous studies have shown upregulation of GRK2 is essentially involved in the pathogenesis of HF by further diminishing adrenergic responsiveness. Indeed, 2 recent clinical studies indicate that lymphocyte GRK2 decreases with angiotensin-converting enzyme inhibitor therapy in class II HF 34 and that lymphocyte and myocardial GRK2 levels decrease, whereas ␤AR responsiveness increases, after mechanical LV support in end-stage HF. 26 Using heterozygous GRK2 knockouts with 50% diminished GRK2 expression, recent studies have established a dose-response between GRK2 levels and suppression of cardiac contractile function in HF. 27, 28 Indeed, in various experimental models of HF, inhibition of GRK2 with GRK2-ct improves cardiac function by restoring ␤AR signaling. 6, 35 Thus, upregulation of GRK2 and resultant ␤AR desensitization are initially adaptive compensation of the heart, but when exaggerated, causes cardiac maladaptive remodeling and HF.
The beneficial effect of restoration of ␤AR signaling through inhibiting GRK2 activity appears to contradict clinical convention that ␤-blockade is widely used to treat patients with HF and that chronic ␤-agonist (ie, catecholamine) stimulation leads to deleterious effects. However, a close inspection reveals that the detrimental effects of catecholamines are mainly mediated by stimulation of ␤ 1 ARs, which triggers myocyte apoptosis and arrhythmogenic events. In contrast, the present study has shown that inhibition of GRK2-mediated ␤ 2 AR-coupled G i signaling can normalize cardiac contractile response and ameliorate maladaptive remodeling. In this regard, our recent in vivo studies on a rat ischemic HF model have demonstrated that selective activation of ␤ 2 AR can, indeed, improve cardiac function and reduce maladaptive remodeling as well as arrhythmogenic events. 36 Taken together, we propose that a combination of GRK2 inhibition and ␤ 2 AR activation with ␤ 1 -blocker therapy may provide a more effective therapy for the treatment of HF.
Role of GRK-Mediated ␤ 2 AR Phosphorylation in Promoting G i -Biased Signaling and Its Implications in HF
Although ␤AR is classically viewed as a prototypical G scoupled receptor, compelling evidence indicates that ␤ 2 AR couples dually to G s and G i proteins. 37 We and others have previously shown that G i -biased ␤ 2 AR signaling may protect cardiomyocytes against various insulting stimuli induced apoptosis. 38, 39 In addition, it has been shown that inhibition of G i signaling worsens cardiac outcomes in response to ischemia/reperfusion injury and myocardial infarction 40 and that GRK inhibition with the peptide inhibitor GRK2-ct is cardioprotective, at least in part, due to increasing G i -biased ␤ 2 AR signaling. 41 Furthermore, recent studies have shown that ablation of ␤ 2 AR, indeed, worsens pressure overload-induced cardiac hypertrophy and remodeling in mice. 42 These previous studies seem to contradictory to the present conclusion that an augmentation in GRK-mediated ␤ 2 AR-G i signaling contributes to cardiac maladaptive remodeling and failure under TAC in PKA-TG mice. To address this question, we have examined the potential effect of TAC on myocardial cell apoptosis in all 4 groups of mice (NTG, WT-TG, GRK-TG, and PKA-TG) and found no genotype-related difference in TAC-triggered myocardial apoptosis (Online Figure IV) . In addition, we have shown that PTX enhances ISO-induced cardiomyocyte death, whereas ␤ 2 AR stimulation with zinterol protects cardiomyocytes in PTX-sensitive manner (Online Figure V) , consistent with the previous notion that ␤ 2 AR-G i signaling is cardiac protective. However, cardiomyocytes from PKA-TG mice are more vulnerable than those from other groups (Online Figure V) , although ␤ 2 AR-G i signaling is markedly enhanced in PKA-TG mice. Thus, it merits future investigation to elucidate the exact mechanism underlying cardiac maladaptive remodeling and failure associated with enhanced GRK-mediated ␤ 2 AR/G i signaling in PKA-TG mice under TAC.
During prolonged agonist stimulation, GRK2 plays a predominant role in desensitizing ␤ARs and has been implicated as a causal factor of HF, but the underlying etiologic mechanism is unknown until now. Traditionally, it has been shown that GRK-mediated phosphorylation of ␤AR inhibits the interaction between activated receptor and G proteins through recruiting ␤-arrestins, which bind to phosphorylated ␤AR and sterically block the receptor coupling to the ␤ subunit of G s protein. 43 In this study, however, we have provided multiple lines of evidence to show that increased phosphorylation of ␤ 2 AR by GRK facilitates the receptor to G i signaling, which, in turn, results in cardiac contractile dysfunction and maladaptive remodeling. The present findings have also unraveled a novel function of the prototypical GRK, GRK2, in switching G s -to G i -biased ␤ 2 AR signaling. Thus, in addition to PKA, GRK plays an important role in sorting ␤ 2 AR to G i -biased signaling pathway in response to Figure 5 . In vivo cardiac pressure-volume relations in mice with sham operation or 5 weeks after TAC. A, Left ventricular pressure-volume loops show TAC-induced increase in systolic load. In NTG-, WT-TG, and GRK-TG mice, TAC leads to rightward shift of the loops and end-systolic pressure-volume relation, marking hypertrophy remodeling. However, in PKA-TG mice, TAC induces heart failure (HF). B and C, Summary data on systolic function (B) and diastolic function (C). LVSP indicates left ventricular systolic pressure; SV, stroke volume; Ea, arterial elastance (measure of ventricular afterload); EF, ejection fraction; ϩdP/dt, maximum dP/dt; Ees, endsystolic pressure-volume relationship (ESPVR); Eed, end-diastolic pressure-volume relationship (ESDPVR); EDP, end-diastolic pressure; Tau, regression of log (pressure) versus time (Weiss method). All values present meanϮSEM (nϭ8 -13 for each group; *PϽ0.05, **PϽ0.01 versus respective sham; †PϽ0.05, ‡PϽ0.01 versus respective TAC). enhanced catecholamine stimulation, as is the case in the failing heart.
It is noteworthy that whereas the ␤ 1 AR subtype does not couple to G i under normal conditions, ␤ 1 AR-mediated contractile response is cross-inhibited by enhanced G i -biased ␤ 2 AR signaling in the failing heart. 29, 44 The reinforced GRK-dependent G i -biased ␤ 2 AR signaling probably is also responsible for GRK2 overexpression-induced dysfunction of ␤ 1 AR in addition to the defect of ␤ 2 AR contractile response in these transgenic mice. This idea is, indeed, corroborated by the fact that disruption of G i signaling fully rather than partially restores the nonselective ␤AR agonist, ISO, induced positive inotropic effect in transgenic mice overexpressing cardiac GRK2 ( Figure 1C and 1D) . Thus, similar to the situation of the failing heart, 14, 44, 45 enhanced ␤ 2 AR-coupled G i signaling is responsible for the defects of both ␤ 1 AR and ␤ 2 AR signaling in the GRK2 TG mice, and that the previously reported beneficial effects of GRK2-ct in improving the function of the failing heart 23 is mediated, at least in part, by attenuating GRK-dependent G i -biased␤ 2 AR signaling.
It is known that overexpression of ␤ARs may alter their signaling behavior and G protein-coupling properties. 46 Overexpression of the PKA-phosphodeficient ␤ 2 AR mutant in cells and in transgenic mice may complicate our conclusion on the functional consequence of GRK-mediated phosphorylation of ␤ 2 AR in facilitating G i -biased ␤ 2 AR signaling because of possible disruptions of signaling events mediated by other molecules such as G s , ␤-arrestins, and receptor trafficking, 13 although the present study has used WT-TG and GRK2-TG for comparison. This technical limitation should be taken into consideration, when the present data are interpreted.
In summary, we have revealed a novel function of GRK in promoting G i -biased ␤ 2 AR signaling that compromises cardiac reserve and contributes to the pathogenesis of HF. In the failing heart, enhanced expression and activity of GRK2 and G i proteins further promote G i -biased ␤ 2 AR signaling, thus negating ␤ 1 AR-and ␤ 2 AR-mediated cardiac reserve function, resulting in cardiac maladaptive remodeling and failure. These in vitro and in vivo results have not only revealed a fundamental function and new mechanism of action of GRK2, the best characterized GRKs, in facilitating G i -biased ␤ 2 AR signaling but also defined the ␤ 2 AR-G i signaling as an essential link between pathological upregulation of GRK and the development of HF. As a well-established pathogenic factor of HF, GRK2 and resultant G i -biased ␤ 2 AR signaling Figure 6 . TAC-induced heart failure is associated with greater increases in G i and GRK2 expression, and inhibition of G i signaling with PTX restores cardiac contractility and blocks the decay of cAMP accumulation by ISO in PKA-TG mouse hearts. A, Representative Western blots using a specific antibody reacting with GRK2 or G i␣3 to assay GRK2 and G i␣3 protein levels in hearts from NTG, WT-TG, PKA-TG, or GRK2-TG mice. Beta-actin was used as a control for protein loading. B, Average data (nϭ4 -6 for each group, *PϽ0.01 versus respective sham;
†PϽ0.05 versus the other 3 groups with TAC). C, PTX restored the blunted cardiac contractility in PKA-TG mice subjected to 1 week or 5 weeks of TAC (nϭ5-13, *PϽ0.05 versus respective sham; †PϽ0.05 versus respective TAC). Note that PTX treatment fully restored contractile response in the early stage heart failure in PKA-TG mice subjected to 1 week of TAC and significantly improved cardiac contractility even in the later stage of heart failure in PKA-TG mice after 5 weeks of TAC. D, The decay of cAMP accumulation evoked by ISO (left panel) is prevented by PTX treatment (right panel). Cardiomyocytes from NTG, WT-, PKA-, and GRK-TG mice were stimulated with isoproterenol (ISO, 10 mol/L). At each indicated time point, cells were treated with 200 mol/L of IBMX (3-isobutyl-1-methylxanthine) for 5 minutes before stopping reaction to accumulate cAMP. Note that the decay of cAMP response is accelerated in cardiomyocytes from PKA-TG mice compared with that of other groups and that this genotypespecific difference is prevented by PTX treatment. *PϽ0.05 versus the other 3 strains.
